MB Generational Wealth LLC Makes New $3.72 Million Investment in Gossamer Bio, Inc. $GOSS

MB Generational Wealth LLC acquired a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,414,824 shares of the company’s stock, valued at approximately $3,721,000. Gossamer Bio comprises about 2.4% of MB Generational Wealth LLC’s portfolio, making the stock its 11th largest position.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Legal & General Group Plc purchased a new position in shares of Gossamer Bio during the second quarter worth $26,000. Banco BTG Pactual S.A. acquired a new stake in Gossamer Bio during the second quarter worth about $27,000. Ciovacco Capital Management LLC purchased a new position in Gossamer Bio during the third quarter valued at approximately $27,000. Drive Wealth Management LLC lifted its holdings in Gossamer Bio by 52.7% in the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after acquiring an additional 8,797 shares during the period. Finally, Brighton Jones LLC purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Down 7.0%

GOSS opened at $2.26 on Monday. The company has a market cap of $523.09 million, a PE ratio of -3.28 and a beta of 1.93. Gossamer Bio, Inc. has a twelve month low of $0.76 and a twelve month high of $3.87. The company has a 50-day moving average price of $2.96 and a 200 day moving average price of $2.67.

Analysts Set New Price Targets

Several research firms have recently weighed in on GOSS. Barclays began coverage on shares of Gossamer Bio in a report on Tuesday, January 27th. They set an “overweight” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.